Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.75 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.67 |
| ▸ | FXR2 | P51116 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19620265 | 1.00 | NR1H4 (0.75) | NR1H4HSD17B13FXR2 | |
| SCHEMBL15929519 | 1.00 | NR1H4 (0.75) | NR1H4HSD17B13FXR2 | |
| SCHEMBL14641899 | 0.97 | NR1H4 (0.80) | NR1H4HSD17B13FXR2 | |
| SCHEMBL14641893 | 0.97 | NR1H4 (0.80) | NR1H4HSD17B13FXR2 | |
| SCHEMBL17087813 | 0.97 | NR1H4 (0.80) | NR1H4HSD17B13FXR2 | |
| SCHEMBL15929531 | 0.93 | NR1H4 (0.72) | NR1H4HSD17B13 | |
| SCHEMBL15929549 | 0.93 | NR1H4 (0.72) | NR1H4HSD17B13 | |
| SCHEMBL15929530 | 0.91 | NR1H4 (0.90) | NR1H4HSD17B13FXR2 | |
| SCHEMBL15929542 | 0.91 | NR1H4 (0.90) | NR1H4HSD17B13FXR2 | |
| SCHEMBL19620259 | 0.91 | NR1H4 (0.90) | NR1H4HSD17B13FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180200243-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-9820979-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170143684-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-9539244-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| US-20150342930-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9139539-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140221659-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | NR1H4 10/4885HSD17B13 1618/4885FXR2 6/4885 |
| US-20180200243-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885FXR2 5/4885 |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | NR1H4 1/4885HSD17B13 102/4885FXR2 2/4885 |
| US-20150342930-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885FXR2 5/4885 |
| US-20170143684-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885FXR2 5/4885 |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | NR1H4, FXR2, FXR1 | NR1H4 1/4885HSD17B13 573/4885FXR2 2/4885 |
| US-20140221659-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885FXR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.